BioSpace News Archive

Ended 3rd quarter with $201.2 million in cash and cash equivalents

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced updated interim results from the ongoing global, open-label, multicohort Phase 1 clinical trial of its anti-PD-L1 antibody, cosibelimab, in patients with advanced cancers, including a cohort of patients with previously untreated high PD-L1 expressing advanced non-small cell lung cancer (“NSCLC”).

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from multiple presentations at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020).

Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the third quarter ended September 30, 2020 and provided an update of its ongoing development activities.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today presented new interim clinical data for the tumor infiltrating lymphocyte (TIL) therapy LN-145

BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that two posters on BXCL701, the Company’s investigational, oral innate immunity activator, will be presented at the Society for Immunotherapy of Cancer’s (“SITC”) 35th Anniversary Annual Meeting

Homology Medicines, Inc., a genetic medicines company, announced that Pfizer Inc. has agreed to make a $60 million equity investment in Homology.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced its participation in the following upcoming virtual investor conferences:

DTx Pharma, Inc., a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced the appointment of Denise Bevers as Chief Operating Officer.

Data Marks the First Proof of Concept for a BiTE® Molecule in Thoracic Malignancy and Further Demonstrates Potential of BiTE® Immuno-Oncology Platform in Solid Tumors